Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Distribution of clinical manifestations according to HLA-B*5 1 and HLA-A status

From: Associations between the HLA-Apolymorphism and the clinical manifestations of Behcet's disease

Patient subset n(%) of clinical manifestations OR (95% CI) P
  Skin lesions   
B*51+ A*02:07+ 8/8 (100) NA 0.20
B*51- A*02:07+ 17/19 (89.5) 2.86 (0.63 to 13.10) 0.24
B*51+ A*02:07- 63/73 (86.3) 2.12 (0.97 to 4.64) 0.055
B*51- A*02:07- 92/123 (74.8) (referent)  
  Uveitis   
B*51+ A*26:01+ 4/7 (57.1) 3.10 (0.66 to 14.53) 0.21
B*51- A*26:01+ 11/19 (57.9) 3.20 (1.19 to 8.59) 0.017
B*51+ A*26:01- 33/74 ((44.6) 1.87 (1.03 to 3.40) 0.039
B*51- A*26:01- 37/123 (30.1) (referent)  
  1. CI, confidence intervals; NA, not applicable; OR, odds ratio.